“We are pleased with the progress we have made over the past several months which includes the advancement of the SRF388 and SRF114 clinical trials and the significant efforts we have undertaken towards completing our planned merger with Coherus BioSciences,” said Rob Ross, M.D., chief executive officer of Surface. “To truly realize the potential of SRF388 and SRF114, it is essential that these molecules are developed with both the resources and companion drugs needed to successfully advance them through the clinic and bring them to the market. We firmly believe that with Coherus, our programs will have the best possible opportunity to benefit patients and realize value for our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SURF:
- Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
- Surface Oncology downgraded to Hold from Buy at JonesResearch
- Coherus Biosciences price target lowered to $22 from $24 at Truist
- Surface Oncology downgraded to Neutral from Outperform at Wedbush
- Surface Oncology downgraded to Neutral from Outperform at Baird
Questions or Comments about the article? Write to editor@tipranks.com